top of page

Everest Medicines' CFO Ian Woo, and an expert in China biotech, describes the company's and the country's evolution from in-licensing assets from the West to developing its own innovative medicines

  • Sep 9, 2025
  • 1 min read

He discusses key assets Everest has in-licensed, including NEFCON and etrasimod, and describes the innovative work Everest is doing in mRNA today. Plus, his thoughts on the efficiency of working in China, and the global dynamics of China-U.S. partnerships in medicine.




Coverage brought to you by:


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page